Imugene announces a$80 million institutional placement
Filed with ASX · · 5 pages · English
Story so far
Earlier from Imugene
- Imugene doses first patient in nextHERIZON Phase 2 trial
- Imugene Dose Escalates in Phase I Clinical Trial of VAXINIA
- Annual Report and Appendix 4E
- First cohort 3 patient dosed in clinical trial of checkvacc
- Imugene Presents New PD1-Vaxx Data at the 2022 WCLC
Later from Imugene
- Prospectus for the issue of institutional placement options
- OGTR grants VAXINIA DIR licence allowing trial expansion
- First patient IV dosed in VAXINIA Phase 1 clinical trial
- Preclinical trial of ALA iNKT therapy and IMU onCARlytics
- First patient dosed in VAXINIA intratumoral cohort 2
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene